Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
Clinical trial NCT01026051 · TERMINATED
Trial details
- NCT number
- NCT01026051
- Sponsor
- Mannkind Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-01
- Primary completion
- 2011-09-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.